Coherence Neuro has begun human trials of a brain-computer interface designed to detect and potentially prevent tumor growth through electrical stimulation.
The biotech company implanted the devices in three patients as part of early-stage testing. The technology aims to use electrical signals to monitor brain activity and intervene before cancer cells proliferate.
Coherence Neuro's approach represents a novel application of brain-computer interfaces, which have traditionally focused on restoring mobility or communication for paralyzed patients. The implants could eventually alert physicians to tumor development in real time.
The trial marks an expansion into therapeutic uses beyond neural rehabilitation. If successful, the technology could offer a new method for early cancer detection and treatment in high-risk patients.
Details on patient selection criteria and trial duration remain limited. The company plans to monitor outcomes over coming months to assess both safety and efficacy of the implant system.
Semiconductor stocks suffered one of their worst trading days this year, raising questions about the sustainability of equity market gains that have been heavily concentrated in a narrow group of high-performing tech names.
The FDA has dropped its complaint against fitness tracker company Whoop over its blood pressure monitoring feature, reversing its earlier demand that the tool be disabled.
Google's Pixel 10A is getting a $100 price cut at Amazon, dropping from $499 to $399. The discount makes the phone a more compelling value after a lukewarm launch.